Sigma-Aldrich To Sell Pfizer's Bioactive Small Molecule Compounds

St. Louis: Sigma-Aldrich has entered into an agreement with Pfizer under which Sigma-Aldrich will sell approximately 100 Pfizer-developed small molecule compounds to life science researchers for target characterization, assay development, screening and in vivo animal model applications.

Under the agreement between the two companies, the Pfizer compounds, which include patented and approved drug molecules such as atorvastatin, sildenafil and celecoxib, will be made available to the research community while still on patent, in some cases for the first time.

The inclusion of these Pfizer compounds provides authentic material that will help advance researchers understanding of biological systems. The Pfizer compounds will be sold worldwide directly through Sigma-Aldrich as in-stock, pre-packaged items and, upon request, in bulk, and will also be mapped to genes and associated pathways and interactors via Sigma-Aldrich?s award-winning online search platform,.While the initial agreement includes approximately 100 Pfizer compounds, Sigma-Aldrich expects to add further Pfizer compounds on a regular basis.